Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.

295Background: While the introduction of durvalumab consolidation therapy shifted the treatment paradigm for unresectable stage III NSCLC, few studies have examined real-world use of durvalumab in ...